Search Results - "NEGRIER, C."

Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH by Dargaud, Y., Wolberg, A. S., Gray, E., Negrier, C., Hemker, H. C.

Get full text

Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography by RUGERI, L., LEVRAT, A., DAVID, J. S., DELECROIX, E., FLOCCARD, B., GROS, A., ALLAOUCHICHE, B., NEGRIER, C.

“…Background: Reagent‐supported thromboelastometry with the rotation thrombelastography (e.g. ROTEM®) is a whole blood assay that evaluates the visco‐elastic…”
Get full text

Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients by Levrat, A., Gros, A., Rugeri, L., Inaba, K., Floccard, B., Negrier, C., David, J.-S.

“…Blood loss and uncontrollable bleeding are major factors affecting survival in trauma patients. Because treatment with antifibrinolytic drugs may be effective,…”
Get full text

The benefits of exercise for patients with haemophilia and recommendations for safe and effective physical activity by Negrier, C., Seuser, A., Forsyth, A., Lobet, S., Llinas, A., Rosas, M., Heijnen, L.

“…Summary Most health care professionals involved in the management of people with haemophilia (PWH) believe that exercise is beneficial and its practice is…”
Get full text

Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement by Iorio, A., Iserman, E., Blanchette, V., Dolan, G., Escuriola Ettingshausen, C., Hermans, C., Negrier, C., Oldenburg, J., Reininger, A., Rodriguez‐Merchan, C., Spannagl, M., Valentino, L. A., Young, G., Steinitz‐Trost, K. N., Gringeri, A.

“…Background Prophylactic replacement with factor concentrate is the optimal treatment for persons with severe haemophilia to avoid or minimize bleeding. This…”
Get full text

Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in previously treated patients with severe haemophilia A by Dargaud, Y., Negrier, C., Rusen, L., Windyga, J., Georgiev, P., Bichler, J., Solomon, C., Knaub, S., Lissitchkov, T., Klamroth, R.

“…Introduction For individuals with haemophilia A, prophylaxis with factor VIII (FVIII) is typically directed towards trough activity >1 IU/dL; however, some…”
Get full text

Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc by Berntorp, E., Negrier, C., Gozzi, P., Blaas, P-M., Lethagen, S.

“…Introduction Aim: To use Pharmacokinetic (PK) simulations to illustrate potential differences in clinical outcomes between prophylaxis with conventional…”
Get full text

Optimizing on-demand treatment with NovoSeven® room temperature stable by NEGRIER, C.

“…Patients with haemophilia can now look forward to greater life expectancy than ever before – a development that can be attributed to improved healthcare…”
Get full text

Diagnosis and management challenges in patients with mild haemophilia A and discrepant FVIII measurements by Trossaert, M., Lienhart, A., Nougier, C., Fretigny, M., Sigaud, M., Meunier, S., Fouassier, M., Ternisien, C., Negrier, C., Dargaud, Y.

“…Summary Thirty per cent of patients with mild haemophilia A (MHA) present markedly different FVIII: C level when assayed by one‐stage clotting and two‐stage…”
Get full text

Seventy-two total knee arthroplasties performed in patients with haemophilia using continuous infusion by Chevalier, Y., Dargaud, Y., Lienhart, A., Chamouard, V., Negrier, C.

“…Background and Objectives  Total knee replacement (TKR) is the treatment of choice in case of end‐stage knee arthropathy, the main complication of haemophilia…”
Get full text

Thrombin generation testing in haemophilia comprehensive care centres by DARGAUD, Y., NEGRIER, C.

“…Haemophilia comprehensive care centres (HCCC) were first created more than 50 years ago. Their first objective was educating the patient and healthcare…”
Get full text

Standardisation of thrombin generation test - which reference plasma for TGT?: An international multicentre study by Dargaud, Y, Luddington, R, Gray, E, Lecompte, T, Siegemund, T, Baglin, T, Hogwood, J, Regnault, V, Siegemund, A, Negrier, C

“…Abstract We have previously shown that standardisation and normalization of results improve the intercentre variability of the calibrated automated thrombin…”
Get full text

Pharmacokinetics of a novel extended half‐life glycoPEGylated factor IX, nonacog beta pegol (N9‐GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials by Tiede, A., Abdul‐Karim, F., Carcao, M., Persson, P., Clausen, W. H. O., Kearney, S., Matsushita, T., Negrier, C., Oldenburg, J., Santagostino, E., Young, G.

“…Introduction Nonacog beta pegol (N9‐GP) is a glycoPEGylated recombinant factor IX (FIX) with an extended half‐life developed for routine prophylaxis and the…”
Get full text

Characterization of five associations of F8 missense mutations containing FVIII B domain mutations by Jourdy, Y., Nougier, C., Roualdes, O., Fretigny, M., Durand, B., Negrier, C., Vinciguerra, C.

“…Introduction Haemophilia A (HA) is a bleeding disorder due to an absence or a reduced activity of coagulation factor VIII (FVIII) caused by mutations in F8…”
Get full text

The association of haemophilic arthropathy with Health-Related Quality of Life: a post hoc analysis by Fischer, K., de Kleijn, P., Negrier, C., Mauser-Bunschoten, E. P., van der Valk, P. R., van Galen, K. P. M., Willemze, A., Schutgens, R.

“…Background The aim of replacement therapy in haemophilia is to improve Health‐Related Quality of Life (HRQoL) by preventing bleeding and arthropathy. However,…”
Get full text

Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials by Negrier, C., Young, G., Abdul Karim, F., Collins, P. W., Hanabusa, H., Colberg, T., Goldman, B., Walsh, C. E.

“…Background The paradigm™2 and 4 phase 3 clinical trials investigated the safety and efficacy of nonacog beta pegol, a recombinant glycoPEGylated factor IX…”
Get full text

Thrombin generation in patients with factor XI deficiency and clinical bleeding risk by RUGERI, L., QUÉLIN, F., CHATARD, B., DE MAZANCOURT, P., NEGRIER, C., DARGAUD, Y.

“…Factor XI (FXI) deficiency is a rare bleeding disorder. Most patients with FXI deficiency are mild bleeders but certain patients with similar FXI activity…”
Get full text

Study of six patients with complete F9 deletion characterized by cytogenetic microarray: role of the SOX3 gene in intellectual disability by Jourdy, Y., Chatron, N., Carage, M.‐L., Fretigny, M., Meunier, S., Zawadzki, C., Gay, V., Negrier, C., Sanlaville, D., Vinciguerra, C.

“…Essentials Some hemophilia B (HB) patients with complete F9 deletion present with intellectual disability (ID). We delineate six F9 complete deletions and…”
Get full text

Chromogenic analysis of FIX activity in haemophilia B patients treated with nonacog beta pegol by Young, G., Ezban, M., Clausen, W. H. O., Negrier, C., Oldenburg, J., Shima, M.

Get full text

The first recombinant FVIII produced in human cells - an update on its clinical development programme by Valentino, L. A., Negrier, C., Kohla, G., Tiede, A., Liesner, R., Hart, D., Knaub, S.

“…Summary The development of inhibitors and the need for frequent venous access for FVIII injection are major challenges in current haemophilia treatment…”
Get full text